Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.83M | -24.16M | -12.24M | -9.47M | -5.07M |
| Total Depreciation and Amortization | -5.16M | 571.00K | 2.56M | 22.39M | 22.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.63M | 74.33M | 69.84M | 58.68M | 64.12M |
| Change in Net Operating Assets | 14.62M | 13.60M | 1.62M | -9.11M | -15.71M |
| Cash from Operations | 48.25M | 64.35M | 61.78M | 62.49M | 65.67M |
| Capital Expenditure | -43.74M | -36.02M | -36.40M | -27.95M | -23.91M |
| Sale of Property, Plant, and Equipment | 43.00K | 45.00K | 47.00K | 32.00K | 22.00K |
| Cash Acquisitions | -18.73M | -18.73M | -18.73M | -18.73M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.32M | -5.66M | -8.35M | -13.19M | -28.98M |
| Cash from Investing | -63.74M | -60.37M | -63.43M | -59.83M | -52.87M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -113.00K | -115.00K | -114.00K | -107.00K | -87.00K |
| Issuance of Common Stock | 5.22M | 4.62M | 2.84M | 4.70M | 4.83M |
| Repurchase of Common Stock | -15.74M | -11.66M | -10.67M | -10.78M | -10.80M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 190.00K | 190.00K | 190.00K | 190.00K | -- |
| Cash from Financing | -10.44M | -6.96M | -7.76M | -6.00M | -6.06M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.93M | -2.98M | -9.40M | -3.34M | 6.74M |